{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:25:22Z","timestamp":1791300322737,"version":"4.1.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.semcancer.2011.09.012","type":"journal-article","created":{"date-parts":[[2011,9,29]],"date-time":"2011-09-29T01:46:26Z","timestamp":1317260786000},"page":"229-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Immunology and immunotherapy of neuroblastoma"],"prefix":"10.1016","volume":"21","author":[{"given":"Robert C.","family":"Seeger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2011.09.012_bib0005","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJM198510313131802","article-title":"Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas","volume":"313","author":"Seeger","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0010","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/jnci\/87.19.1470","article-title":"Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis","volume":"87","author":"Shimada","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0015","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.1200\/JCO.2005.05.183","article-title":"Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study","volume":"23","author":"Schmidt","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0020","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1200\/JCO.2005.05.571","article-title":"Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group","volume":"23","author":"London","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0025","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group","volume":"341","author":"Matthay","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0030","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2007.13.8925","article-title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group Study","volume":"27","author":"Matthay","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0035","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0040","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1073\/pnas.60.4.1231","article-title":"Demonstration of cell-bound and humoral immunity against neuroblastoma cells","volume":"60","author":"Hellstrom","year":"1968","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0045","first-page":"415","article-title":"The implications of immune reactions to neuroblastoma","volume":"66","author":"Bill","year":"1969","journal-title":"Surgery"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0022-3468(70)90266-6","article-title":"Evidence for immune reactions to neuroblastoma and future possibilities for investigation","volume":"5","author":"Bill","year":"1970","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0055","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0140-6736(71)91606-0","article-title":"Special pattern of widespread neuroblastoma with a favourable prognosis","volume":"1","author":"D\u2019Angio","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0060","first-page":"49","article-title":"Spontaneous regression of neuroblastoma","volume":"44","author":"Evans","year":"1976","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0065","first-page":"5","article-title":"Spontaneous regression of cancer and the importance of finding its cause","volume":"44","author":"Cole","year":"1976","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0070","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0075","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1084\/jem.176.5.1453","article-title":"A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E","volume":"176","author":"Traversari","year":"1992","journal-title":"J Exp Med"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0080","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.immunol.24.021605.090733","article-title":"Human T cell responses against melanoma","volume":"24","author":"Boon","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0085","first-page":"5544","article-title":"An overview of the MAGE gene family with the identification of all human members of the family","volume":"61","author":"Chomez","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0090","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1034\/j.1600-065X.2002.18803.x","article-title":"Cancer\/testis antigens: an expanding family of targets for cancer immunotherapy","volume":"188","author":"Scanlan","year":"2002","journal-title":"Immunol Rev"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0095","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/(SICI)1097-0215(19961021)69:5<403::AID-IJC9>3.0.CO;2-9","article-title":"Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma","volume":"69","author":"Corrias","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/(SICI)1097-0215(19961021)69:5<375::AID-IJC4>3.0.CO;2-2","article-title":"MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors","volume":"69","author":"Ishida","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0105","first-page":"2205","article-title":"Expression and clinical relevance of NY-ESO-1 MAGE-1 and MAGE-3 in neuroblastoma","volume":"19","author":"Soling","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0110","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00262-004-0603-z","article-title":"Expression of MHC class I MHC class II, and cancer germline antigens in neuroblastoma","volume":"54","author":"Wolfl","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0115","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-011-1037-z","article-title":"MAGE-A1 MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing","author":"Bao","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0120","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1158\/1078-0432.CCR-07-0686","article-title":"The universal character of the tumor-associated antigen survivin","volume":"13","author":"Andersen","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0125","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1200\/JCO.2005.05.3314","article-title":"Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma","volume":"24","author":"Coughlin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0130","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1593\/neo.06415","article-title":"Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications","volume":"8","author":"Morandi","year":"2006","journal-title":"Neoplasia"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0135","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00262-008-0496-3","article-title":"Immunotherapy of neuroblastoma by an interleukin-21-secreting cell vaccine involves survivin as antigen","volume":"57","author":"Croce","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0140","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ijc.24291","article-title":"Survivin minigene DNA vaccination is effective against neuroblastoma","volume":"125","author":"Fest","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0145","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1158\/1535-7163.MCT-08-0109","article-title":"A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity","volume":"7","author":"Huebener","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0150","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/1535-7163.MCT-09-0107","article-title":"Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma","volume":"8","author":"Huebener","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0155","first-page":"1908","article-title":"Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes","volume":"60","author":"Sarkar","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00002371-199402000-00001","article-title":"Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors","volume":"15","author":"Katsanis","year":"1994","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00002371-199603000-00004","article-title":"Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-gamma","volume":"19","author":"Bausero","year":"1996","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0170","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood.V92.6.1941","article-title":"IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma","volume":"92","author":"Bowman","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0175","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1089\/hum.1998.9.9-1303","article-title":"Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma","volume":"9","author":"Bowman","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0180","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1182\/blood-2002-08-2493","article-title":"Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma","volume":"101","author":"Rousseau","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/01.cji.0000211335.14385.57","article-title":"Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin","volume":"30","author":"Russell","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0190","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/CJI.0b013e3181869893","article-title":"A phase 1\/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma","volume":"31","author":"Russell","year":"2008","journal-title":"J Immunother"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0195","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1073\/pnas.81.20.6476","article-title":"Weak HLA and beta 2-microglobulin expression of neuronal cell lines can be modulated by interferon","volume":"81","author":"Lampson","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0200","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4049\/jimmunol.135.1.242","article-title":"Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes","volume":"135","author":"Main","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0205","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.1158\/1078-0432.CCR-09-0829","article-title":"Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivo","volume":"15","author":"Reid","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0210","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2004.11.064","article-title":"Mechanisms of immune evasion of human neuroblastoma","volume":"228","author":"Raffaghello","year":"2005","journal-title":"Cancer Lett"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0215","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1038\/sj.onc.1208594","article-title":"Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications","volume":"24","author":"Raffaghello","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0220","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1593\/neo.04316","article-title":"Downregulation and\/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma","volume":"6","author":"Raffaghello","year":"2004","journal-title":"Neoplasia"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0225","doi-asserted-by":"crossref","first-page":"12640","DOI":"10.1073\/pnas.0405025101","article-title":"Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis","volume":"101","author":"Castriconi","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0230","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/eji.200839028","article-title":"B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction","volume":"39","author":"Leitner","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0235","doi-asserted-by":"crossref","first-page":"6433","DOI":"10.1158\/0008-5472.CAN-06-4588","article-title":"Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release","volume":"67","author":"Morandi","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0240","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semcancer.2007.07.004","article-title":"Soluble HLA-G: are they clinically relevant?","volume":"17","author":"Pistoia","year":"2007","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0245","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.semcancer.2008.03.004","article-title":"Macrophage polarization in tumour progression","volume":"18","author":"Sica","year":"2008","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0250","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clim.2010.10.005","article-title":"Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans","volume":"140","author":"Metelitsa","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0255","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.4049\/jimmunol.167.6.3114","article-title":"Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells","volume":"167","author":"Metelitsa","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0260","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1084\/jem.20031462","article-title":"Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2","volume":"199","author":"Metelitsa","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0265","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1172\/JCI30751","article-title":"Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma","volume":"117","author":"Song","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0270","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1172\/JCI37869","article-title":"Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages","volume":"119","author":"Song","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0275","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P","article-title":"The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma","volume":"79","author":"Coca","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0280","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V","article-title":"Prognostic value of intratumoral natural killer cells in gastric carcinoma","volume":"88","author":"Ishigami","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0285","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0169-5002(01)00292-6","article-title":"Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer","volume":"35","author":"Villegas","year":"2002","journal-title":"Lung Cancer"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0290","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/labinvest.3700055","article-title":"Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis","volume":"84","author":"Menon","year":"2004","journal-title":"Lab Invest"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0295","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration\u2013effect relationship","volume":"64","author":"Dall\u2019Ozzo","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0300","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0305","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.2005.06.059","article-title":"Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia","volume":"23","author":"Treon","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0310","first-page":"189","article-title":"Interferon-gamma upregulates the susceptibility of human neuroblastoma cells to interleukin-2-activated natural killer cells","volume":"8","author":"Handgretinger","year":"1989","journal-title":"Nat Immun Cell Growth Regul"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0315","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/bjc.1993.173","article-title":"Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication","volume":"67","author":"Foreman","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0320","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1182\/blood.V83.5.1323.1323","article-title":"Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12","volume":"83","author":"Rossi","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0325","doi-asserted-by":"crossref","first-page":"7330","DOI":"10.1158\/1078-0432.CCR-09-1720","article-title":"KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma","volume":"15","author":"Venstrom","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0330","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1158\/0008-5472.CAN-10-2211","article-title":"Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14. 18-IL2 immunotherapy","volume":"70","author":"Delgado","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0335","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/eji.200324705","article-title":"Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors","volume":"34","author":"Andre","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0340","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.emboj.7600019","article-title":"Unravelling natural killer cell function: triggering and inhibitory human NK receptors","volume":"23","author":"Moretta","year":"2004","journal-title":"EMBO J"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0345","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0952-7915(03)00039-6","article-title":"Natural killer cell receptor signaling","volume":"15","author":"Lanier","year":"2003","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0350","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0165-5728(00)00221-6","article-title":"Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines","volume":"107","author":"Sivori","year":"2000","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0355","doi-asserted-by":"crossref","first-page":"9180","DOI":"10.1158\/0008-5472.CAN-04-2682","article-title":"Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction","volume":"64","author":"Castriconi","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0360","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00002371-199205000-00006","article-title":"Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial","volume":"11","author":"Truitt","year":"1992","journal-title":"J Immunother (1991)"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0365","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1002\/1097-0142(19950615)75:12<2959::AID-CNCR2820751225>3.0.CO;2-R","article-title":"A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study","volume":"75","author":"Bauer","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0370","first-page":"1445","article-title":"Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation","volume":"23","author":"Marti","year":"1995","journal-title":"Exp Hematol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0375","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0380","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":"Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0385","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2010.30.8387","article-title":"Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed\/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report","volume":"29","author":"Berg","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0390","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/sj.bjc.6601579","article-title":"Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers","volume":"90","author":"Bartlett","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0395","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0400","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0405","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0410","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0415","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0420","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1126\/science.424740","article-title":"Hybrid myelomas producing antibodies against a human neuroblastoma antigen present on fetal brain","volume":"203","author":"Kennett","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0425","first-page":"2714","article-title":"Common antigenic determinants on human melanoma, glioma, neuroblastoma, and sarcoma cells defined with monoclonal antibodies","volume":"41","author":"Seeger","year":"1981","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0430","first-page":"827","article-title":"Analysis of human tumor cells for Ia-like antigens with monoclonal antibodies","volume":"66","author":"Howe","year":"1981","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0435","doi-asserted-by":"crossref","first-page":"983","DOI":"10.4049\/jimmunol.128.2.983","article-title":"Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody","volume":"128","author":"Seeger","year":"1982","journal-title":"J Immunol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0440","first-page":"5914","article-title":"Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients","volume":"44","author":"Schulz","year":"1984","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0445","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1073\/pnas.83.20.7893","article-title":"Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin","volume":"83","author":"Honsik","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0450","doi-asserted-by":"crossref","first-page":"10299","DOI":"10.1016\/S0021-9258(18)67524-6","article-title":"Characterization of a unique glycoprotein antigen expressed on the surface of human neuroblastoma cells","volume":"261","author":"Mujoo","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0455","first-page":"1098","article-title":"Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth","volume":"47","author":"Mujoo","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0460","doi-asserted-by":"crossref","first-page":"11943","DOI":"10.1016\/S0021-9258(18)37877-3","article-title":"A human brain glycoprotein related to the mouse cell adhesion molecule L1","volume":"263","author":"Wolff","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0465","first-page":"2642","article-title":"Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells","volume":"45","author":"Cheung","year":"1985","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-291X(85)80117-0","article-title":"Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell","volume":"127","author":"Saito","year":"1985","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0475","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.1987.5.9.1430","article-title":"Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma","volume":"5","author":"Cheung","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0480","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1056\/NEJM199101243240403","article-title":"Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma","volume":"324","author":"Moss","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0485","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/sj.bjc.6605029","article-title":"Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force","volume":"100","author":"Beiske","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0490","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2000.18.24.4067","article-title":"Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study","volume":"18","author":"Seeger","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0495","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.V84.2.380.380","article-title":"Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells","volume":"84","author":"Rill","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0500","first-page":"5882","article-title":"Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads","volume":"46","author":"Reynolds","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0505","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0140-6736(85)91906-3","article-title":"Detection of a tumour-associated ganglioside in plasma of patients with neuroblastoma","volume":"1","author":"Ladisch","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0510","first-page":"440","article-title":"Expression of GD2 ganglioside by untreated primary human neuroblastomas","volume":"46","author":"Wu","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0515","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF01756188","article-title":"A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14. G2a","volume":"35","author":"Handgretinger","year":"1992","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0520","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.1994.12.1.184","article-title":"Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors","volume":"12","author":"Murray","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0525","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0959-8049(94)00413-Y","article-title":"A phase I study of human\/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma","volume":"31A","author":"Handgretinger","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0530","first-page":"4865","article-title":"Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes","volume":"51","author":"Kushner","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0535","first-page":"144","article-title":"Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells","volume":"51","author":"Barker","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0540","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0165-2478(89)90194-6","article-title":"Lysis of neuroblastoma cells by the ADCC-reaction: granulocytes of patients with chronic granulomatous disease are more effective than those of healthy donors","volume":"22","author":"Bruchelt","year":"1989","journal-title":"Immunol Lett"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0545","first-page":"5234","article-title":"Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2","volume":"50","author":"Hank","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0550","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood.V73.7.1936.1936","article-title":"GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma","volume":"73","author":"Kushner","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0555","first-page":"362","article-title":"A mechanism for neutrophil-mediated lysis of human neuroblastoma cells","volume":"53","author":"Barker","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0560","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1182\/blood.V99.11.4166","volume":"99","author":"Metelitsa","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0565","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00002371-199401000-00004","article-title":"Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro","volume":"15","author":"Hank","year":"1994","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0570","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/(SICI)1097-0142(19970715)80:2<317::AID-CNCR21>3.0.CO;2-W","article-title":"A phase I\/IB trial of murine monoclonal anti-GD2 antibody 14. G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group","volume":"80","author":"Frost","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0575","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1200\/JCO.1998.16.6.2169","article-title":"Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma","volume":"16","author":"Yu","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0580","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1200\/JCO.2000.18.24.4077","volume":"18","author":"Ozkaynak","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0585","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1200\/JCO.2006.10.3564","article-title":"Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group","volume":"27","author":"Gilman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0590","doi-asserted-by":"crossref","first-page":"9626","DOI":"10.1073\/pnas.91.20.9626","article-title":"A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice","volume":"91","author":"Sabzevari","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0595","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s002620050256","article-title":"Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2","volume":"42","author":"Pancook","year":"1996","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0600","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1172\/JCI119107","article-title":"Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy","volume":"98","author":"Becker","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0605","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1158\/1078-0432.CCR-05-2000","article-title":"A phase I clinical trial of the hu14. 18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group","volume":"12","author":"Osenga","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0610","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1200\/JCO.2009.27.8861","article-title":"Antitumor activity of hu14. 18-IL2 in patients with relapsed\/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study","volume":"28","author":"Shusterman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0615","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","article-title":"Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model","volume":"11","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0620","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0625","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.21468","article-title":"Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo","author":"Zhang","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0630","doi-asserted-by":"crossref","first-page":"11712","DOI":"10.1158\/0008-5472.CAN-05-1657","article-title":"Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications","volume":"65","author":"Tai","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0635","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1365-2141.2008.07548.x","article-title":"The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia","volume":"144","author":"Lapalombella","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0640","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-010-0919-9","article-title":"Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers","volume":"60","author":"Wu","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0645","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/PPO.0b013e3181c51f37","article-title":"T-cell engineering for cancer immunotherapy","volume":"15","author":"Sadelain","year":"2009","journal-title":"Cancer J"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0650","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0655","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ijc.1457","article-title":"Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes","volume":"94","author":"Rossig","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0660","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood.V99.6.2009","article-title":"Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy","volume":"99","author":"Rossig","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0665","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0670","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/jgm.489","article-title":"Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma","volume":"6","author":"Gonzalez","year":"2004","journal-title":"J Gene Med"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0675","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0680","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0685","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/mt.2010.185","article-title":"T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms","volume":"18","author":"Sun","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0690","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0695","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0700","doi-asserted-by":"crossref","DOI":"10.3791\/2540","article-title":"Expansion, purification, and functional assessment of human peripheral blood NK cells","author":"Somanchi","year":"2011","journal-title":"J Vis Exp"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0705","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0710","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nm0311-285","article-title":"B cells and macrophages in cancer: yin and yang","volume":"17","author":"Mantovani","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0715","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/jnci\/djj330","article-title":"Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification","volume":"98","author":"Asgharzadeh","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0720","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.4049\/jimmunol.181.6.3784","article-title":"TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells","volume":"181","author":"Trotta","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0725","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.4049\/jimmunol.155.3.1066","article-title":"Regulation of NK cell functions by TGF-beta 1","volume":"155","author":"Bellone","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0730","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ccr.2009.12.019","article-title":"FcRgamma activation regulates inflammation-associated squamous carcinogenesis","volume":"17","author":"Andreu","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0735","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10555-010-9223-6","article-title":"Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity","volume":"29","author":"DeNardo","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0740","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.cji.0000211336.91513.dd","article-title":"CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma","volume":"30","author":"Johnson","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0745","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/ijc.25140","article-title":"Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice","volume":"127","author":"Croce","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semcancer.2011.09.012_bib0750","doi-asserted-by":"crossref","first-page":"6952","DOI":"10.1182\/blood-2010-12-326108","article-title":"Depletion of CD25+ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma","volume":"117","author":"Jing","year":"2011","journal-title":"Blood"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X11000617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X11000617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:27:53Z","timestamp":1760916473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X11000617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":150,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S1044579X11000617"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2011.09.012","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunology and immunotherapy of neuroblastoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2011.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}